MEDSIR together with Oncoclinicas & Co., leads independent clinical research at the largest European congress of medical oncology, with the presentation of 12 studies, marking a new scientific milestone for the company. The ABIGAIL study stands out for its innovative strategy, evaluating the combination of abemaciclib with endocrine therapy as an alternative treatment without chemotherapy in first-line HR+/HER2- advanced breast cancer with poor prognosis criteria.
The PECATI study, focused on patients with advanced thymic tumors, a rare type of cancer, has demonstrated an 88% rate of progression-freedisease in the first 5 months. The company hosted MEDTalks, a satellite symposium dedicated to advancing brain metastasis research, addressing a critical unmet need in solid tumors such as lung, breast, and skin cancers . BARCELONA , Sept.
16, 2024 /PRNewswire/ -- MEDSIR, a leading company dedicated to promoting independent clinical research in oncology internationally and part of Oncoclinicas & Co, the largest hospital group dedicated to cancer treatment in Latin America , participated this year in the congress of the European Society for Medical Oncology (ESMO), held in Barcelona , presenting 12 new studies addressing different types of cancer. The studies presented by MEDSIR reflect its pivotal approach and commitment to innovation in personalized treatments, highlighting advances in prostate ( ZZFIRST study), breast (ABIGAIL), thymic (PECATI) and lung ( I3Lung .) cancers.
Amon.